DiaMedica Therapeutics (NASDAQ:DMAC) Stock Price Down 1.5% – Should You Sell?

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) shares were down 1.5% during mid-day trading on Tuesday . The stock traded as low as $6.52 and last traded at $6.64. Approximately 206,697 shares traded hands during mid-day trading, a decline of 0% from the average session volume of 207,556 shares. The stock had previously closed at $6.74.

Analyst Upgrades and Downgrades

DMAC has been the subject of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised shares of DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $12.00.

DiaMedica Therapeutics Trading Up 3.0%

The company has a 50-day moving average of $6.52 and a 200-day moving average of $7.03. The firm has a market capitalization of $350.76 million, a price-to-earnings ratio of -9.17 and a beta of 0.97.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its earnings results on Wednesday, May 6th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). On average, research analysts forecast that DiaMedica Therapeutics, Inc. will post -0.86 earnings per share for the current year.

Hedge Funds Weigh In On DiaMedica Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. acquired a new stake in shares of DiaMedica Therapeutics in the 3rd quarter worth about $27,000. China Universal Asset Management Co. Ltd. acquired a new position in DiaMedica Therapeutics during the 4th quarter valued at about $29,000. Bank of America Corp DE grew its position in DiaMedica Therapeutics by 3,710.3% in the 2nd quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock worth $33,000 after purchasing an additional 8,274 shares during the last quarter. Farther Finance Advisors LLC acquired a new stake in shares of DiaMedica Therapeutics in the fourth quarter valued at approximately $34,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of DiaMedica Therapeutics in the second quarter valued at approximately $49,000. Institutional investors and hedge funds own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.